Common Cancer-associated Antigens Vaccine Market
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Tecemotide
1.2.3 Astuprotimut-R
1.2.4 Tertomotide
1.2.5 Nelipepimut-S
1.2.6 Others
1.3 Market by Application
1.3.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Pediatrics
1.3.3 Adults
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Perspective (2017-2028)
2.2 Common Cancer-associated Antigens (CAAs) Vaccine Growth Trends by Region
2.2.1 Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Region (2017-2022)
2.2.3 Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Region (2023-2028)
2.3 Common Cancer-associated Antigens (CAAs) Vaccine Market Dynamics
2.3.1 Common Cancer-associated Antigens (CAAs) Vaccine Industry Trends
2.3.2 Common Cancer-associated Antigens (CAAs) Vaccine Market Drivers
2.3.3 Common Cancer-associated Antigens (CAAs) Vaccine Market Challenges
2.3.4 Common Cancer-associated Antigens (CAAs) Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Revenue
3.1.1 Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Revenue (2017-2022)
3.1.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Players (2017-2022)
3.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Common Cancer-associated Antigens (CAAs) Vaccine Revenue
3.4 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Concentration Ratio
3.4.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Common Cancer-associated Antigens (CAAs) Vaccine Revenue in 2021
3.5 Common Cancer-associated Antigens (CAAs) Vaccine Key Players Head office and Area Served
3.6 Key Players Common Cancer-associated Antigens (CAAs) Vaccine Product Solution and Service
3.7 Date of Enter into Common Cancer-associated Antigens (CAAs) Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Common Cancer-associated Antigens (CAAs) Vaccine Breakdown Data by Type
4.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Type (2017-2022)
4.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Type (2023-2028)
5 Common Cancer-associated Antigens (CAAs) Vaccine Breakdown Data by Application
5.1 Global Common Cancer-associated Antigens (CAAs) Vaccine Historic Market Size by Application (2017-2022)
5.2 Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2017-2028)
6.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type
6.2.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2017-2022)
6.2.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2023-2028)
6.2.3 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2017-2028)
6.3 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application
6.3.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2017-2022)
6.3.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2023-2028)
6.3.3 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2017-2028)
6.4 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country
6.4.1 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2017-2022)
6.4.2 North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2017-2028)
7.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type
7.2.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2017-2022)
7.2.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2023-2028)
7.2.3 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2017-2028)
7.3 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application
7.3.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2017-2022)
7.3.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2023-2028)
7.3.3 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2017-2028)
7.4 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country
7.4.1 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2017-2022)
7.4.2 Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2017-2028)
8.2 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type
8.2.1 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2017-2028)
8.3 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application
8.3.1 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2017-2028)
8.4 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region
8.4.1 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2017-2028)
9.2 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type
9.2.1 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2017-2022)
9.2.2 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2023-2028)
9.2.3 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2017-2028)
9.3 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application
9.3.1 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2017-2022)
9.3.2 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2023-2028)
9.3.3 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2017-2028)
9.4 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country
9.4.1 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2017-2022)
9.4.2 Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size (2017-2028)
10.2 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type
10.2.1 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type (2017-2028)
10.3 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application
10.3.1 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application (2017-2028)
10.4 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country
10.4.1 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Seattle Genetics
11.1.1 Seattle Genetics Company Details
11.1.2 Seattle Genetics Business Overview
11.1.3 Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.1.4 Seattle Genetics Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
11.1.5 Seattle Genetics Recent Developments
11.2 Merck Serono
11.2.1 Merck Serono Company Details
11.2.2 Merck Serono Business Overview
11.2.3 Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.2.4 Merck Serono Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
11.2.5 Merck Serono Recent Developments
11.3 Merck KGaA
11.3.1 Merck KGaA Company Details
11.3.2 Merck KGaA Business Overview
11.3.3 Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.3.4 Merck KGaA Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
11.3.5 Merck KGaA Recent Developments
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Details
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.4.4 GlaxoSmithKline Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
11.4.5 GlaxoSmithKline Recent Developments
11.5 KAEL-GemVax
11.5.1 KAEL-GemVax Company Details
11.5.2 KAEL-GemVax Business Overview
11.5.3 KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.5.4 KAEL-GemVax Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
11.5.5 KAEL-GemVax Recent Developments
11.6 SELLAS Life Sciences
11.6.1 SELLAS Life Sciences Company Details
11.6.2 SELLAS Life Sciences Business Overview
11.6.3 SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.6.4 SELLAS Life Sciences Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
11.6.5 SELLAS Life Sciences Recent Developments
11.7 Celldex
11.7.1 Celldex Company Details
11.7.2 Celldex Business Overview
11.7.3 Celldex Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.7.4 Celldex Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
11.7.5 Celldex Recent Developments
11.8 Immatics Biotechnologies
11.8.1 Immatics Biotechnologies Company Details
11.8.2 Immatics Biotechnologies Business Overview
11.8.3 Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Introduction
11.8.4 Immatics Biotechnologies Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
11.8.5 Immatics Biotechnologies Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Tecemotide
Table 3. Key Players of Astuprotimut-R
Table 4. Key Players of Tertomotide
Table 5. Key Players of Nelipepimut-S
Table 6. Key Players of Others
Table 7. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 8. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region (2017-2022)
Table 11. Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region (2023-2028)
Table 13. Common Cancer-associated Antigens (CAAs) Vaccine Market Trends
Table 14. Common Cancer-associated Antigens (CAAs) Vaccine Market Drivers
Table 15. Common Cancer-associated Antigens (CAAs) Vaccine Market Challenges
Table 16. Common Cancer-associated Antigens (CAAs) Vaccine Market Restraints
Table 17. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Share by Players (2017-2022)
Table 19. Global Top Common Cancer-associated Antigens (CAAs) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Common Cancer-associated Antigens (CAAs) Vaccine as of 2021)
Table 20. Ranking of Global Top Common Cancer-associated Antigens (CAAs) Vaccine Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Common Cancer-associated Antigens (CAAs) Vaccine Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Common Cancer-associated Antigens (CAAs) Vaccine Product Solution and Service
Table 24. Date of Enter into Common Cancer-associated Antigens (CAAs) Vaccine Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Type (2017-2022)
Table 28. Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Market Share by Type (2023-2028)
Table 30. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Share by Application (2017-2022)
Table 32. Global Common Cancer-associated Antigens (CAAs) Vaccine Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Common Cancer-associated Antigens (CAAs) Vaccine Revenue Share by Application (2023-2028)
Table 34. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2017-2022) & (US$ Million)
Table 35. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2023-2028) & (US$ Million)
Table 36. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2017-2022) & (US$ Million)
Table 37. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2023-2028) & (US$ Million)
Table 38. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2017-2022) & (US$ Million)
Table 39. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2023-2028) & (US$ Million)
Table 40. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2017-2022) & (US$ Million)
Table 41. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2023-2028) & (US$ Million)
Table 42. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2017-2022) & (US$ Million)
Table 43. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2023-2028) & (US$ Million)
Table 44. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2017-2022) & (US$ Million)
Table 45. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2023-2028) & (US$ Million)
Table 46. Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2017-2022) & (US$ Million)
Table 47. Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2023-2028) & (US$ Million)
Table 48. Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2017-2022) & (US$ Million)
Table 49. Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2023-2028) & (US$ Million)
Table 50. Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2017-2022) & (US$ Million)
Table 51. Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Region (2023-2028) & (US$ Million)
Table 52. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2017-2022) & (US$ Million)
Table 53. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2023-2028) & (US$ Million)
Table 54. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2017-2022) & (US$ Million)
Table 55. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2023-2028) & (US$ Million)
Table 56. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2017-2022) & (US$ Million)
Table 57. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Type (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Application (2023-2028) & (US$ Million)
Table 62. Middle East and Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2017-2022) & (US$ Million)
Table 63. Middle East and Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size by Country (2023-2028) & (US$ Million)
Table 64. Seattle Genetics Company Details
Table 65. Seattle Genetics Business Overview
Table 66. Seattle Genetics Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 67. Seattle Genetics Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022) & (US$ Million)
Table 68. Seattle Genetics Recent Developments
Table 69. Merck Serono Company Details
Table 70. Merck Serono Business Overview
Table 71. Merck Serono Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 72. Merck Serono Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022) & (US$ Million)
Table 73. Merck Serono Recent Developments
Table 74. Merck KGaA Company Details
Table 75. Merck KGaA Business Overview
Table 76. Merck KGaA Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 77. Merck KGaA Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022) & (US$ Million)
Table 78. Merck KGaA Recent Developments
Table 79. GlaxoSmithKline Company Details
Table 80. GlaxoSmithKline Business Overview
Table 81. GlaxoSmithKline Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 82. GlaxoSmithKline Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022) & (US$ Million)
Table 83. GlaxoSmithKline Recent Developments
Table 84. KAEL-GemVax Company Details
Table 85. KAEL-GemVax Business Overview
Table 86. KAEL-GemVax Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 87. KAEL-GemVax Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022) & (US$ Million)
Table 88. KAEL-GemVax Recent Developments
Table 89. SELLAS Life Sciences Company Details
Table 90. SELLAS Life Sciences Business Overview
Table 91. SELLAS Life Sciences Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 92. SELLAS Life Sciences Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022) & (US$ Million)
Table 93. SELLAS Life Sciences Recent Developments
Table 94. Celldex Company Details
Table 95. Celldex Business Overview
Table 96. Celldex Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 97. Celldex Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022) & (US$ Million)
Table 98. Celldex Recent Developments
Table 99. Immatics Biotechnologies Company Details
Table 100. Immatics Biotechnologies Business Overview
Table 101. Immatics Biotechnologies Common Cancer-associated Antigens (CAAs) Vaccine Product
Table 102. Immatics Biotechnologies Revenue in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022) & (US$ Million)
Table 103. Immatics Biotechnologies Recent Developments
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Type: 2021 VS 2028
Figure 2. Tecemotide Features
Figure 3. Astuprotimut-R Features
Figure 4. Tertomotide Features
Figure 5. Nelipepimut-S Features
Figure 6. Others Features
Figure 7. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Application: 2021 VS 2028
Figure 8. Pediatrics Case Studies
Figure 9. Adults Case Studies
Figure 10. Common Cancer-associated Antigens (CAAs) Vaccine Report Years Considered
Figure 11. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 12. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Region: 2021 VS 2028
Figure 14. Global Common Cancer-associated Antigens (CAAs) Vaccine Market Share by Players in 2021
Figure 15. Global Top Common Cancer-associated Antigens (CAAs) Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Common Cancer-associated Antigens (CAAs) Vaccine as of 2021)
Figure 16. The Top 10 and 5 Players Market Share by Common Cancer-associated Antigens (CAAs) Vaccine Revenue in 2021
Figure 17. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY (2017-2028) & (US$ Million)
Figure 18. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Market Share by Type (2017-2028)
Figure 19. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Market Share by Application (2017-2028)
Figure 20. North America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Share by Country (2017-2028)
Figure 21. United States Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. Canada Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY (2017-2028) & (US$ Million)
Figure 24. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size Market Share by Type (2017-2028)
Figure 25. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size Market Share by Application (2017-2028)
Figure 26. Europe Common Cancer-associated Antigens (CAAs) Vaccine Market Size Share by Country (2017-2028)
Figure 27. Germany Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. France Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. U.K. Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Italy Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Russia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Nordic Countries Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Asia-Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY (2017-2028) & (US$ Million)
Figure 34. Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size Market Share by Type (2017-2028)
Figure 35. Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size Market Share by Application (2017-2028)
Figure 36. Asia Pacific Common Cancer-associated Antigens (CAAs) Vaccine Market Size Share by Region (2017-2028)
Figure 37. China Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Japan Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. South Korea Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Southeast Asia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. India Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Australia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 43. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY (2017-2028) & (US$ Million)
Figure 44. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Market Share by Type (2017-2028)
Figure 45. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Market Share by Application (2017-2028)
Figure 46. Latin America Common Cancer-associated Antigens (CAAs) Vaccine Market Size Share by Country (2017-2028)
Figure 47. Mexico Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Brazil Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Middle East & Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY (2017-2028) & (US$ Million)
Figure 50. Middle East and Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size Market Share by Type (2017-2028)
Figure 51. Middle East and Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size Market Share by Application (2017-2028)
Figure 52. Middle East and Africa Common Cancer-associated Antigens (CAAs) Vaccine Market Size Share by Country (2017-2028)
Figure 53. Turkey Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Saudi Arabia Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. UAE Common Cancer-associated Antigens (CAAs) Vaccine Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. Seattle Genetics Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
Figure 57. Merck Serono Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
Figure 58. Merck KGaA Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
Figure 59. GlaxoSmithKline Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
Figure 60. KAEL-GemVax Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
Figure 61. SELLAS Life Sciences Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
Figure 62. Celldex Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
Figure 63. Immatics Biotechnologies Revenue Growth Rate in Common Cancer-associated Antigens (CAAs) Vaccine Business (2017-2022)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Industry Market Size
